New patent covers updated aerosol delivery system and design until 2039 WARRINGTON, Pa., Feb. 16, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that the United States Patent and Trademark Office (USPTO) […]
Coronary/Structural Heart
Heart Valve Disease Awareness Day Campaign Celebrates Fifth Anniversary with Focus on Health Disparities
Advocates Continue to Drive Forward Heart Valve Disease Awareness, While Highlighting the Inequities in Risk Factors, Diagnosis, and Treatment Faced by Black Americans WASHINGTON, Feb. 16, 2021 /PRNewswire/ — On Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual HVD Awareness Day (“Valve Disease […]
Orsini Specialty Pharmacy Selected To Be The Exclusive Specialty Pharmacy Partner For Evkeeza™ (evinacumab-dgnb)
ELK GROVE VILLAGE, Ill., Feb. 16, 2021 /PRNewswire/ — Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Regeneron Pharmaceuticals, Inc. as the exclusive specialty pharmacy partner for EvkeezaTM (evinacumab-dgnb). Evkeeza is approved by the U.S. Food and Drug Administration (FDA) as an adjunct […]
WeHealth™ Digital Medicine and BioSerenity Initiate a New Phase to Accelerate Cardioskin™ Commercialization
BioSerenity acquires Cardioskin™ global distribution rights PARIS and ATLANTA, Feb. 16, 2021 /PRNewswire/ — WeHealth™ Digital Medicine (e-health division of the Servier Group) and BioSerenity announced today that BioSerenity gains global distribution rights for Cardioskin™, the first WeHealth™ digital Solution co-developped with a start-up, to accelerate the commercialization of Cardioskin™. After successfully collaborating to develop the Cardioskin™, the […]
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3 Expanded indication enables potential treatment of more adults with […]
VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
The favorable opinion of the CPP (French ethic committee) and authorization from the ANSM (French National Agency for the Safety of Medicines and Health Products) allow the operational launch of the HEART study. The HEART study will be conducted under the scientific expertise of Jean-Marie Bard, Professor and Hospital Practitioner […]
Thrombolytic Science Reinforces Its IP Portfolio with Patents in Europe, the Commonwealth of Independent States and Japan
New Patents to Support Global Partnering of Novel Bio-inspired Clot-dissolving Therapy CAMBRIDGE, MA, February 10, 2021 / B3C newswire / — Thrombolytic Science, LLC (TSI) today announced the granting of three new patents during the last 12 months. The invention relates to methods and compositions for safe and effective thrombolysis for ischemic […]
Aziyo Biologics Announces Product Design Completion for its Next Generation CanGaroo® Envelope for Implantable Electronic Devices
SILVER SPRING, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product design completion for CanGaroo® with antibiotics, the next generation of the Company’s CanGaroo […]
Olatec Therapeutics LLC Announces a Scientific Publication on the Positive Results in the First Known Clinical Trial with a Selective Oral NLRP3 Inhibitor, Dapansutrile, in Patients with Heart Failure
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in subjects with stable heart failure with reduced ejection fraction (HFrEF) Antonio Abbate MD PhD, the Principal Investigator, is Professor of Medicine and Medical Director of the Clinical Research Unit at […]
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ — Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LDL-C) In pivotal Phase 3 HoFH trial, adding Evkeeza to standard lipid-lowering therapies reduced LDL-C by nearly half at 24 […]
Recent
Galaxy Therapeutics Achieves CE Mark for SEAL™ Embolization System, Enabling Commercial Launch Across Europe and International Markets
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
Galaxy Therapeutics Achieves CE Mark for SEAL™ Embolization System, Enabling Commercial Launch Across Europe and International Markets
Popular
- No commented posts yet